ImmunityBio (IBRX)
Healthcare
Close on Nov 9, 2026 (from our latest article): $7.11
- Market value
- $7.6Bat the Nov 9 close
- Revenue growth
- +121%12 months to Sep 30, 2026 (10-Q)
- FCF margin
- −163%12 months to Sep 30, 2026 (10-Q)
- Net debt
- $927Mat Sep 30, 2026
- Worst fall since listing
- −97.1%Jul 29, 2015 to Jun 10, 2019; back to that high in Feb 2021
About the company
Website (external site)Investor relations (external site)SEC filings (external site)
The Long View
What the filings say about the story, dilution and cash runway.
No Long View yet. Request one →
Our View Opinion
Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.
No Our View yet. Request one →
Long-term fundamentals
Annual results for ImmunityBio, FY2013–FY2025, as reported in its 10-K filings.
Revenue and free cash flow
Revenue went from $0.6M in FY2013 to $113M in FY2025.
Free cash flow was positive in 0 of the 13 years shown; FY2025: −$309M.
Margins
Margins are not charted: in FY2025 the operating loss (−$256M) was larger than revenue ($113M). The table has each year's figures.
Diluted share count
The diluted share count rose 144% from FY2020 to FY2025, to 920M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $113M | — | −226% | −$351M | −$305M | $4M | −$309M |
| FY2024 | $15M | — | −2334% | −$414M | −$391M | $7M | −$398M |
| FY2023 | $0.6M | — | −58240% | −$583M | −$367M | $31M | −$397M |
| FY2022 | $0.2M | — | −146374% | −$417M | −$338M | $78M | −$416M |
| FY2021 | $0.9M | — | −35362% | −$347M | −$274M | $34M | −$308M |
| FY2020 | $0.6M | — | −36509% | −$222M | −$172M | $2M | −$173M |
| FY2019 | $2M | — | −7096% | −$158M | −$152M | $4M | −$156M |
| FY2018 | $0.0M | — | −209338% | −$96M | −$63M | $13M | −$76M |
| FY2017 | $0.0M | — | −220267% | −$96M | −$49M | $35M | −$84M |
| FY2016 | $0.0M | — | −282955% | −$121M | −$39M | $7M | −$45M |
| FY2015 | $0.2M | — | −101219% | −$237M | −$25M | $2M | −$28M |
| FY2014 | $0.6M | — | −870% | −$6M | −$5M | $0.2M | −$6M |
| FY2013 | $0.6M | — | — | −$2M | −$0.7M | $0.0M | −$0.7M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | 920M | $243M | $325M | $37M | — | — |
| FY2024 | 700M | $150M | $284M | $34M | — | — |
| FY2023 | 509M | $266M | $577M | $49M | — | — |
| FY2022 | 400M | $107M | $673M | $40M | — | — |
| FY2021 | 389M | $317M | — | $57M | — | $0 |
| FY2020 | 377M | $96M | — | $2M | — | $0 |
| FY2019 | 366M | $113M | — | $3M | — | $3M |
| FY2018 | — | $80M | — | $23M | — | $0.2M |
| FY2017 | — | $158M | — | $37M | — | $15M |
| FY2016 | — | $199M | — | $74M | — | $16M |
| FY2015 | — | $294M | — | $211M | — | $5M |
| FY2014 | — | $59M | — | $0.8M | — | $0 |
| FY2013 | — | $0.3M | — | $0.9M | — | — |
Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 9, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.
- Free cash flow here does not subtract principal payments on finance leases (FY2025: $0M); a company measure that does will be lower by that amount.
Returns by year
| Year | IBRX | S&P 500 |
|---|---|---|
| 2019 | +226.7% | +31.5% |
| 2020 | +251.7% | +18.4% |
| 2021 | −54.4% | +28.7% |
| 2022 | −16.6% | −18.1% |
| 2023 | −1.0% | +26.3% |
| 2024 | −49.0% | +25.0% |
| 2025 | −22.7% | +17.9% |
| 2026 to date | +231.8% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Healthcare
- LEGN Legend Down 16%
- IRTC iRhythm Down 30.7%
- VCYT Veracyte Down 54.3%
- IDXX IDEXX Laboratories Up 21.8%
- PACB PacBio Down 11.4%
Questions about ImmunityBio
- Why did ImmunityBio stock fall on Nov 9, 2026?
- ImmunityBio's sales of Anktiva, its bladder-cancer drug, fell from the second quarter for the first time since its launch, and total revenue of $48.8 million missed the $59.2 million estimate from Fiscal.ai, cited by Stocktwits. The same morning it said a registrational trial in newly diagnosed patients met its main goal, but it gave no response rates. The shares closed down about 18% on a day biotech stocks rose, after rising about 336% from the end of 2025 through Friday (Yahoo Finance closes; our calculation). Read the article →